# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001493152-26-031922
Filing Date
2026-07-02
Accepted
2026-07-02 16:30:32
Documents
17
Period of Report
2026-07-02

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | formdef14a.htm iXBRL | DEF 14A | 641438
2 | GRAPHIC | proxy_001.jpg | GRAPHIC | 536775
3 | GRAPHIC | proxy_002.jpg | GRAPHIC | 284726
| Complete submission text file | 0001493152-26-031922.txt |  | 3353166

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
4 | XBRL SCHEMA FILE | gtbp-20251231.xsd | EX-101.SCH | 7205
5 | XBRL DEFINITION FILE | gtbp-20251231_def.xml | EX-101.DEF | 10051
6 | XBRL LABEL FILE | gtbp-20251231_lab.xml | EX-101.LAB | 71208
7 | XBRL PRESENTATION FILE | gtbp-20251231_pre.xml | EX-101.PRE | 46764
20 | EXTRACTED XBRL INSTANCE DOCUMENT | formdef14a_htm.xml | XML | 90485

Mailing Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111
Business Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

EIN.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40023 | Film No.: 261151882
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)